Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay
Identifieur interne : 000905 ( PascalFrancis/Curation ); précédent : 000904; suivant : 000906Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay
Auteurs : Yanchen Zhou [États-Unis] ; Juliet Agudelo [États-Unis] ; Kai Lu [États-Unis] ; David H. Goetz [États-Unis] ; Elizabeth Hansell [États-Unis] ; Yen Ting Chen [États-Unis] ; William R. Roush [États-Unis] ; James Mckerrow [États-Unis] ; Charles S. Craik [États-Unis] ; Sean M. Amberg [États-Unis] ; Graham Simmons [États-Unis]Source :
- Antiviral research [ 0166-3542 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000082
Links to Exploration step
Pascal:12-0002103Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1><s2>San Francisco, CA 94143</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H." last="Goetz">David H. Goetz</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1><s2>Jupiter, FL 33458</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R." last="Roush">William R. Roush</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1><s2>Jupiter, FL 33458</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S." last="Craik">Charles S. Craik</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M." last="Amberg">Sean M. Amberg</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>SIGA Technologies, Inc</s1><s2>Corvallis, OR 97333</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1><s2>San Francisco, CA 94143</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0002103</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 12-0002103 INIST</idno><idno type="RBID">Pascal:12-0002103</idno><idno type="wicri:Area/PascalFrancis/Corpus">000082</idno><idno type="wicri:Area/PascalFrancis/Curation">000905</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1><s2>San Francisco, CA 94143</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H." last="Goetz">David H. Goetz</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1><s2>Jupiter, FL 33458</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R." last="Roush">William R. Roush</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1><s2>Jupiter, FL 33458</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S." last="Craik">Charles S. Craik</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M." last="Amberg">Sean M. Amberg</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>SIGA Technologies, Inc</s1><s2>Corvallis, OR 97333</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1><s2>San Francisco, CA 94143</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Envelope</term><term>High throughput screening</term><term>Identification</term><term>Inhibitor</term><term>Performance evaluation</term><term>Pseudovirion</term><term>Severe acute respiratory syndrome virus</term><term>Technique</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur</term><term>Virus syndrome respiratoire aigu sévère</term><term>Identification</term><term>Enveloppe</term><term>Pseudovirion</term><term>Antiviral</term><term>Criblage haut débit</term><term>Evaluation performance</term><term>Technique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0></fA01><fA02 i1="01"><s0>ARSRDR</s0></fA02><fA03 i2="1"><s0>Antivir. res.</s0></fA03><fA05><s2>92</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay</s1></fA08><fA11 i1="01" i2="1"><s1>ZHOU (Yanchen)</s1></fA11><fA11 i1="02" i2="1"><s1>AGUDELO (Juliet)</s1></fA11><fA11 i1="03" i2="1"><s1>LU (Kai)</s1></fA11><fA11 i1="04" i2="1"><s1>GOETZ (David H.)</s1></fA11><fA11 i1="05" i2="1"><s1>HANSELL (Elizabeth)</s1></fA11><fA11 i1="06" i2="1"><s1>CHEN (Yen Ting)</s1></fA11><fA11 i1="07" i2="1"><s1>ROUSH (William R.)</s1></fA11><fA11 i1="08" i2="1"><s1>MCKERROW (James)</s1></fA11><fA11 i1="09" i2="1"><s1>CRAIK (Charles S.)</s1></fA11><fA11 i1="10" i2="1"><s1>AMBERG (Sean M.)</s1></fA11><fA11 i1="11" i2="1"><s1>SIMMONS (Graham)</s1></fA11><fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1><s2>San Francisco, CA 94118</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1><s2>San Francisco, CA 94143</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1><s2>San Francisco, CA 94158</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1><s2>Jupiter, FL 33458</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="06"><s1>SIGA Technologies, Inc</s1><s2>Corvallis, OR 97333</s2><s3>USA</s3><sZ>10 aut.</sZ></fA14><fA20><s1>187-194</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18839</s2><s5>354000507853860060</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>3/4 p.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0002103</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Antiviral research</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Inhibiteur</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Inhibitor</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Inhibidor</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Identification</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Identification</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Identificación</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Enveloppe</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Envelope</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Envoltura</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Pseudovirion</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Pseudovirion</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Seudovirión</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Criblage haut débit</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>High throughput screening</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Cribado alta productividad</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Evaluation performance</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Performance evaluation</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Evaluación prestación</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Technique</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Technique</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Técnica</s0><s5>09</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fN21><s1>002</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000905 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000905 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:12-0002103
|texte= Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay
}}
| This area was generated with Dilib version V0.6.33. |  |